

KUROS BIOSCIENCES AG

ISIN: CH0325814116 WKN: 32581411 Asset Class: **Stock**

Company

2024/07/17 17:30:08

Price

12.58 CHF

Difference ▲ 0.96%(0.12)



Contact Details

KUROS BIOSCIENCES LTD.

Tel: +41-44-733-47-47

--

Fax: +41-44-733-47-40

Wagistrasse 25

Web:

<http://www.kurosbiosciences.com>

8952 Schlieren

E-mail: info@kuros.ch

Company Profile

Kuros Biosciences Ltd. operates as biopharmaceutical company, which engages in developing products for tissue repair and bone regeneration. It operates through the following segments: Medical devices, Pharmaceuticals, and Legacy portfolio. The Medical devices segment includes products such as MagnetOs and Attrax. The Pharmaceuticals segment offers Fibrin-PTH, a drug-biologic combination which promotes targeted and controlled bone formation through the induction of osteoprogenitor cell differentiation, enhancement, of osteoblast proliferation and by increasing the lifespan of bone-forming cells. The Legacy portfolio segment is involved in all other products that do not belong to the group's core business strategy. The company was founded by Didier Cowling in 2000 and is headquartered in Schlieren, Switzerland.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	27,194,000		31,393,000		32,892,000	
Common stock capital		3,678,000		3,656,000		3,281,000
Fixed assets	48,712,000		56,626,000		63,424,000	
Equity capital of a company		56,712,000		68,860,000		76,976,000
Cash and cash equivalents	14,208,000		24,065,000		28,623,000	
Accrued liabilities		0		0		353,000
Other assets	-		-		-	
Current liabilities		13,187,000		12,589,000		11,288,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		6,007,000		6,570,000		8,052,000
Different income		-		-		-
Other liabilities		0		0		0
Total assets	75,906,000	75,906,000	88,019,000	88,019,000	96,316,000	96,316,000

Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	5	6	6
Equity ratio	74.71%	78.23%	79.92%
Debt-equity ratio	33.84%	27.82%	25.12%

Others

	2023	2022	2021
Tax Expense Rate	-2.85%	8.73%	21.07%

KUROS BIOSCIENCES AG

ISIN: CH0325814116 WKN: 32581411 Asset Class: Stock

Income statement

	2023	2022	2021
Turnover	33,564,000	17,986,000	13,815,000
Net income	-13,727,000	-14,595,000	-7,541,000
EBIT	-13,479,496	-13,771,393	-8,979,161
Operating income before taxes	-13,347,000	-15,991,000	-9,554,000
Cash Flow	-8,844,000	-7,348,000	-5,453,000
Net interest income	-186,000	-2,545,000	-787,000
Research and development expenses	5,599,000	5,194,000	4,989,000
Income taxes	380,000	-1,396,000	-2,013,000
Result from investments in subsidiaries, associates and other	0	0	0
Revenues per employee	6,875,250	3,070,210	2,358,221

Board of Directors

Joost de Bruijn	Member of the administrative board
Albert Arp	Member of the administrative board
Oliver Walker	Member of the administrative board
Clemens van Blitterswijk	Chairman of the administrative board

Members of Management Board

Chris Fair	Chairman of Managing Board
Philippe Saudan	Member of Executive Committee
Joost de Bruijn	Member of Executive Committee
Daniel Geiger	Member of Executive Committee
John Griffin	Member of Executive Committee
Sjoerd Musters	Member of Executive Committee